# **Deprescribing Self-Efficacy Survey**

### **User Agreement**

Thank you for interest in the Deprescribing Self-Efficacy Survey. We welcome additional psychometric testing and use of the survey in deprescribing evaluation and research. Permission to use the survey is given provided you inform our research team about the context in which you are using the survey (by emailing <a href="mailto:deprescribing@bruyere.org">deprescribing@bruyere.org</a>), and it is correctly cited as follows: Farrell B, Richardson L, Raman-Wilms L, de Launay D, Alsabbagh MW, Conklin J. Self-efficacy for deprescribing: a survey for health care professionals using evidence-based deprescribing guidelines. Research in Social and Administrative Pharmacy. Published online: 2018 Jan;14(1):18-25. doi: 10.1016/j.sapharm.2017.01.003.

#### Introduction

Welcome! Thank you for agreeing to participate in our Deprescribing Self-Efficacy survey. We value your input and appreciate your participation in this process. There are 4 sections.

- Section 1 (this page): generate unique survey ID.
- Section 2: demographics.
- Section 3: practice rating self-efficacy for an unrelated topic.
- Section 4: rate your certainty in your capability to carry out specific deprescribing tasks for four different classes of medications, and under potentially impeding circumstances. For each of the three subsequent survey iterations, you will be asked to complete ratings for the same four classes of medications.

### **Section 1: Generate unique survey ID:**

In order to ensure your confidentiality, please generate a survey code using the following instructions. These same instructions will be used in future surveys to link responses over time:

What is the first letter of the ci	ty you were born in?
What day of the month were y	ou born?
What is the second letter of yo	ur first name?
Combine your responses from	questions 1-3. (eg. F23R) (This is your survey ID)
Please enter your survey ID:	

# **Section 2: Demographics**

Cli O	nician role: Pharmacist
0	Family Physician
0	Geriatrician
0	Nurse Practitioner
0	Other
O	
Ye O	ars of experience working with patients over 65: Less than 5 yrs
0	5 - 9
0	10 - 14
0	15 - 19
0	20 - 24
0	25 yrs or more
Pra	actice Type:
0	Long-Term Care
0	Family Health Team
W	hich of the following best describes how you identify yourself:
0	Male
0	Female
0	Other (e.g. transgender)
Ag	e:
0	Under 34
0	35 - 44
0	45 - 54
0	55 - 64
0	65 and older

# **Section 3: Practice Rating**

To familiarize yourself with the rating form for self-efficacy, please complete this practice item first. Certainty in one's ability to complete a task may depend on the difficulty of the task involved. This practice item will help you practice making assessments of your ability to complete tasks of varying levels of difficulty.

### Physical strength practice item

Please rate how certain you are right now that you can lift the specified weight by recording a number from 0-100 using the scale given below:

0	10	20	30	40	50	60	70	80	90	100
Canno Do at				Mode	erately o	certain			Hi	ighly certain can do
Lift a	10 pou	nd objed	ct							
Lift a	20 pou	nd objed	ct _							
Lift a !	50 pou	nd objed	ct _							
Lift a	80 pou	nd objed	ct							
Lift a	100 po	und obj	ect							
Lift a	150 po	und obj	ect							
Lift a	200 po	und obj	ect							
Lift a	300 po	und obj	ect							

## **Section 4: Deprescribing Self-Efficacy Survey**

This survey is designed to help us gain a better understanding of how clinicians rate their self-efficacy in deprescribing an elderly patient's medication(s) and how that self-efficacy changes over time as clinicians use deprescribing guidelines. Self-efficacy refers to one's belief in their capability to carry out specific tasks. In this case, we are interested in your belief in your capability to carry out the tasks related to deprescribing (tapering or stopping) a medication an elderly patient is currently taking.

### **Class #1: Proton pump inhibitors:** Please rate how certain you are right now that you can carry out these tasks for deprescribing proton pump inhibitors by recording a number, 0 to 100 using the scale given below: 0 10 20 30 40 50 60 70 80 90 100 Cannot Moderately certain Highly certain Do at all can do can do For a patient older than 65 years of age who is taking a proton-pump inhibitor (PPI), I am able to: Item Certainty (0-100) 1. Weigh the benefits vs. harms of continuing the PPI 2. Weigh the benefits vs. harms of deprescribing the PPI 3. Consider the patient's preferences, care goals and life expectancy in deciding whether to continue or deprescribe the PPI 4. Determine whether a non-pharmacological intervention would facilitate deprescribing the PPI 5. Determine the best dosing approach to deprescribing the PPI 6. Develop a monitoring plan to determine the outcome of deprescribing the PPI 7. Negotiate a deprescribing plan for the PPI with the patient and his/her carers 8. Monitor and follow-up to determine the outcome of deprescribing the PPI

9. Determine if PPI tapering should stop, or if the PPI should be restarted

Class	#2: Be	nzodi	azepin	e rece	eptor a	agonist	t type	drugs			
	liazepin		-	_		-		-		ks for depres , 0 to 100 usi	_
0	10	20	30	40	50	60	70	80	90	100	
Cannot Do at a					erately c can do	ertain			Hi	ighly certain can do	
			an 65 ye Item (				ng a ben	zodiaze	pine rec	ceptor agonis	t type drug
1. Weig	gh the b	enefits	vs. harn	ns of co	ntinuin	g the BZ	ZRA				
2. Weig	gh the b	enefits	vs. harn	ns of de	eprescri	bing the	e BZRA				
		•	-			oals and e the BZ	-	oectancy	y in		
	rmine v cribing		-	pharma	acologic	al interv	ention	would f	acilitate	2	
5. Dete	rmine t	he best	dosing	approa	ch to de	eprescri	bing the	e BZRA			
6. Deve	_	ionitori	ng plan	to dete	ermine t	he outc	ome of o	depresc	ribing		
7. Nego	otiate a	depreso	cribing p	olan for	the BZ	RA with	the pat	ient and	l his/he	r	
8. Mon BZRA	itor and	l follow	-up to d	etermi	ne the o	outcome	of depr	escribir	ng the		
9. Dete		f BZRA	taperin	g shoul	d stop, o	or if the	BZRA s	hould b	е		
Class	#3: Sta	atins									
						nat you o				ks for depres	cribing
	-					60	_			100	

Moderately certain

can do

Highly certain

can do

Cannot

Do at all

For a p	atient o	lder tha	an 65 ye	ears of a	age who	is takin	g a stati	in, I am	able to:	Item	Certaint	y (0-100)
1. Wei	gh the b	enefits	vs. harn	ns of co	ntinuin	g the sta	tin					
2. Wei	gh the b	enefits	vs. harr	ns of de	eprescril	bing the	statin					
		-	-		s, care go orescribe		-	ectancy	in			
	ermine v scribing			pharma	acologica	al interv	ention	would fa	icilitate			
5. Dete	ermine t	he best	dosing	approa	ich to de	prescrib	oing the	statin				
6. Dev	-	onitori	ng plan	to dete	ermine t	he outco	ome of d	leprescr	ibing			
7. Neg	7. Negotiate a deprescribing plan for the statin with the patient and his/her carers											
8. Mon	itor and	follow	-up to d	letermi	ne the o	utcome	of depr	escribin	g the			
9. Dete		f statin	taperin	g shoul	d stop, c	or if the s	statin sl	nould be				
	#4: An											
			-	_	t now th er, 0 to 1	-					eprescrib	oing
0	10	20	30	40	50	60	70	80	90	100		
Canno Do at a					erately co	ertain			Hiş	ghly ce can de		
_	oatient o		an 65 ye	ears of a	age who	is takin	g an an	tipsycho	otic, I am	able t	to: Item	
1. Wei	gh the b	enefits	vs. harn	ns of co	ontinuing	g the ant	tipsycho	otic				
2. Wei	gh the b	enefits	vs. harr	ns of de	eprescril	bing the	antipsy	chotic				
		-	-		s, care go prescribe		-	-	in			

	ermine w			_	cologic	al interv	vention	would f	acilitate	
5. Dete	5. Determine the best dosing approach to deprescribing the antipsychotic									
	elop a m tipsycho		ng plan	to dete	rmine t	he outco	ome of c	depresc	ribing	
_	7. Negotiate a deprescribing plan for the antipsychotic with the patient and nis/her carers									
	3. Monitor and follow-up to determine the outcome of deprescribing the antipsychotic									
	ermine if be resta		ychotic	taperir	ng shoul	d stop, o	or if the	antipsy	chotic	
A num	<b>escribi</b> ber of si elderly.		_		-	_				deprescribe medications
	rate hov ing a nu		-	_		-	-	rescribe	medica	ations in the elderly by
0	10	20	30	40	50	60	70	80	90	100
Canno Do at a					rately c can do	ertain			H	ighly certain can do
For a p	atient o	lder tha	ın 65 y	ears of a	age, I an	n able to	depres	cribe a	medicat	tion:
Item										Certainty (0-100)
When	I am con	cerned	about	adverse	drug w	vithdraw	val even	ts		
	I am con being u			exacerb	ations (	of the ur	nderlyin	g condi	tion the	
When medica	disease- ation	specific	clinica	ıl guide	lines red	commer	nd the us	se of a		
When	the med	ication	is coup	led to p	erform	ance inc	licators			
When medica	I receive	little s	upport	from co	olleague	es for sto	opping o	or reduc	ing	
When	I have to	o much	work	to do						

When I am concerned about damage to my provider-patient relationship	
When the patient is resistant to change	
When the patient's family/caregivers are resistant to change	
When there is no literature describing the effects of medication tapering or discontinuation	
When there is no guidance on how to taper or stop a medication	
When I am not the original prescriber of the medication	
When the medication was prescribed by a specialist	
When I am unsure why the medication was started originally	
When the medication is being used to treat an adverse effect of another medication	